BrentuximabVedotin (BV)(Seagen / Takeda)은 Hodgkin Lymphoma 표적 ADC로, Hodgkin Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: ADCC) and antibody-dependent cellular phagocytosis (ADCP), in vitro and in vivo. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 2% (ClinicalTrials.gov NCT03264131). 차별점: novel inhibitor of the respiratory syncytial virus (RSV) L-protein, and a potential oral antiviral against RSV.
Hodgkin Lymphoma
Hodgkin Lymphoma
Active
ADCC) and antibody-dependent cellular phagocytosis (ADCP), in v
vedotin-containing regimen versus standard chem
lentiviral hTERT transduction
humanized biparatopic IgG 1 antibody with an E430G hexamerization-enhancing mutation targeting two non-overla
novel inhibitor of the respiratory syncytial virus (RSV) L-protein, and a potential oral antiviral against RSV
ADCC) and antibody-dependent cellular phagocytosis (ADCP), in vitro and in vivo
CDC) and other fragment crystallizable-mediated effector functions, including antibody-dependent cellular cytotoxicity
biomarker for SCI severity, but further validation in prospective cohorts with matched trauma severity is req
Downregulation of miR-6721-5p in the serum of patients with spinal cord injury and its role in regulating microglial inflammation via
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
BrentuximabVedotin (BV)(Seagen / Takeda)은 Hodgkin Lymphoma 표적 ADC로, Hodgkin Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: ADCC) and antibody-dependent cellular phagocytosis (ADCP), in vitro and in vivo. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 2% (ClinicalTrials.gov NCT03264131). 차별점: novel inhibitor of the respiratory syncytial virus (RSV) L-protein, and a potential oral antiviral against RSV.
Hodgkin Lymphoma
Hodgkin Lymphoma
Active
ADCC) and antibody-dependent cellular phagocytosis (ADCP), in v
vedotin-containing regimen versus standard chem
lentiviral hTERT transduction
humanized biparatopic IgG 1 antibody with an E430G hexamerization-enhancing mutation targeting two non-overla
novel inhibitor of the respiratory syncytial virus (RSV) L-protein, and a potential oral antiviral against RSV
ADCC) and antibody-dependent cellular phagocytosis (ADCP), in vitro and in vivo
CDC) and other fragment crystallizable-mediated effector functions, including antibody-dependent cellular cytotoxicity
biomarker for SCI severity, but further validation in prospective cohorts with matched trauma severity is req
Downregulation of miR-6721-5p in the serum of patients with spinal cord injury and its role in regulating microglial inflammation via
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.